It is shown that eGATA3 is associated with poor clinical outcome and remodels the luminal transcriptional program, leading to attenuation of estrogen-responsive transcription and progressive loss of luminal differentiation.
Abstract
GATA3, one of the most frequently mutated transcription factors in breast cancers, is a master regulator of luminal epithelial identity. Unlike many truncating and splice-site GATA3 mutations that disrupt one of the two zinc finger DNA-binding domains, C-terminal extension mutations (eGATA3) retain both of them. This raises the question of whether the eGATA3 mutants can alter transcriptional regulation and thereby exert distinct functional effects. Here, we integrate patient tumor-derived transcription and chromatin accessibility profiling with cell line derived genome-wide mapping of GATA3 occupancy and single-cell multiomics to define the regulatory consequences of eGATA3. We show that eGATA3 is associated with poor clinical outcome and remodels the luminal transcriptional program, leading to attenuation of estrogen-responsive transcription and progressive loss of luminal differentiation. Mechanistically, eGATA3 maintains widespread chromatin occupancy but redistributes GATA3 binding across different classes of regulatory elements, with preferential loss at AP-1 motif-enriched sites and gain at FOX-associated enhancers, along with coordinated remodeling of chromatin accessibility. These changes rewire the luminal regulatory landscape, destabilizing lineage identity without inducing complete lineage conversion. Together, our findings identify eGATA3 as a mechanistically distinct class of GATA3 mutation that promotes lineage plasticity through redistribution of genomic occupancy rather than loss of DNA-binding function alone.
It is shown that p63 reorganizes 3D chromatin topology in squamous cell carcinoma through cooperation with the tumor-selective partner TF, FOXK1, which defines an epigenetic mechanism by which a lineage master TF and tumor-restricted partner TF reshape 3D chromatin structure to drive oncogenic transcription, with impli...
N. Jung, V. Lopez-Pajares, L. Donohue et al.· Science Advances· 0 citations
The androgen receptor (AR) is a key regulator of prostate cancer progression, yet the relationship between AR promoter methylation, chromatin state, and receptor expression across distinct tumor phenotypes remains incompletely understood. We performed an integrative in silico analysis of the AR promoter region spanning...
Aleksey M. Krasnyi, Roman Ivanov, E. Minskaia· International Journal of Mol...· 0 citations
An evidence-weighted, locus- and complex-centered framework to reconcile the MED1 paradox is advanced and it is proposed that MED1 output is determined by lineage-specific transcription-factor recruitment, genomic occupancy, signaling-dependent modification, chromatin state, and cellular context.
Zhe Li, Zhaosong Meng, Lei Sui et al.· Cancer Cell International· 0 citations
Background GATA-binding protein 3 (GATA3) is a pivotal transcriptional regulator during mammary gland development and serves as a core biomarker in breast cancer. Although traditionally recognized for maintaining luminal differentiation, its high mutation frequency reveals a complex, dual role in tumorigenesis. Methods...
Jun-Juan Tan, Wei-Han Chen, Kai-Yan Song et al.· Frontiers in Cell and Develo...· 0 citations